Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by National Bank of Canada FI

National Bank of Canada FI increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 161.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 116,227 shares of the biopharmaceutical company’s stock after purchasing an additional 71,838 shares during the quarter. National Bank of Canada FI owned 0.11% of Regeneron Pharmaceuticals worth $105,185,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of REGN. Eudaimonia Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 1.2% in the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 11 shares during the period. Drive Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.0% in the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 12 shares during the period. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. LCM Capital Management Inc lifted its holdings in Regeneron Pharmaceuticals by 2.5% during the 4th quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 12 shares in the last quarter. Finally, Sutton Wealth Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.1 %

Shares of REGN traded up $19.39 on Friday, hitting $957.00. 547,373 shares of the stock traded hands, compared to its average volume of 509,442. The firm has a market capitalization of $105.04 billion, a P/E ratio of 28.27, a P/E/G ratio of 2.74 and a beta of 0.17. The company has a quick ratio of 4.94, a current ratio of 6.40 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $998.33. The stock’s 50 day moving average is $943.75 and its two-hundred day moving average is $897.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $10.96 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Barclays lifted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Finally, Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Buying and Selling

In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,095 shares of company stock valued at $9,664,476. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.